Verbatim response from Claude
Compounded Tirzepatide Availability
This is a quickly evolving situation, so here's the current picture:
What Happened
The FDA removed tirzepatide (Zepbound/Mounjaro) from its drug shortage list in late 2024, which means most compounding pharmacies must stop making it. The FDA set a compliance deadline, and enforcement has been ongoing.
Still Potentially Legitimate Options
503B Outsourcing Facilities (more regulated than standard compounding pharmacies) may still have limited windows, but availability is shrinking.
Some telehealth platforms that were offering it include:
- Hims & Hers
- LifeMD/GoGoMeds
- Mochi Health
- Henry Meds
However, many have already discontinued compounded tirzepatide offerings.
Honest Advice
- Call and verify directly - the situation changes weekly
- Be cautious of any service still aggressively marketing it, as they may be operating outside compliance
- Eli Lilly's savings programs for brand-name Zepbound may be worth checking if cost is the concern (cards can reduce cost significantly)
Bottom Line
Legitimate compounded tirzepatide is largely phased out. Brand-name Zepbound through proper channels is the safer path right now.
Would you like help finding manufacturer savings programs?